RightFit
RecruitingPhase not listed

Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study looks at how the brain changes in people getting chemotherapy for colon or rectal cancer at Parkview Cancer Institute. The goal is to find helpful tests to identify people at risk for thinking and memory problems from cancer treatment.

The purpose of this research study is to see how the brain changes in patients receiving chemotherapy (cytotoxic drug) treatment for colon or rectal cancer at Parkview Cancer Institute. This information will be used to identify helpful tests to diagnose individuals at risk for developing difficulties with thinking and memory due to their cancer treatments.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Be able to give written consent to join before study screening and allow the use of private health information.
  • Have colon or rectal cancer confirmed by testing a tissue sample.
  • Be scheduled to get cancer-killing chemotherapy, including capecitabine, oxaliplatin, 5-fluorouracil, or irinotecan.
  • Have never received cancer-killing chemotherapy before joining.

Who can't join

  • Have had chemotherapy, radiation treatment, immune-based cancer treatment, or experimental drugs before.
  • Have problems with mental ability that the lead study doctor believes would prevent you from completing surveys.
  • Be pregnant or breastfeeding.
  • Have cancer known to have spread to the brain.
  • Do not speak English.
  • Have a diagnosed brain or thinking disorder, including a brain injury, Alzheimer's, Parkinson's, Huntington's, or Creutzfeldt-Jakob disease.
  • Be judged not suitable for this study by the lead study doctor or study coordinator.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Signed written informed consent must be obtained and documented according to International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the local regulatory requirements, and permission to use private health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA) prior to study-specific screening procedures. Must be able to provide study-specific informed consent prior to study entry. * A histologically-confirmed colorectal tumor * Patients who will be treated with cytotoxic chemotherapies including Capecitabine, Oxaliplatin, 5 fluorouracil, and Irinotecan are eligible. * Patients must not have received cytotoxic chemotherapy previous to enrollment. Exclusion Criteria: * Prior administration of anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents * Patients having mental incompetence as assessed by study PI, which would hinder completion of the surveys * Pregnant or breastfeeding * Any known brain metastases * Non-English speaking patients * Patients who have been diagnosed with any neuro-cognitive disorder including traumatic brain injuries, Alzheimer's disease, Parkinson's disease, Huntington's disease, and Creutzfeldt-Jakob disease. * Patients deemed inappropriate to participate in this study by the study PI or coordinator will be excluded.

Study sites (1)

IN